FR08C0034I1 - Utilisation du composant neurotoxique de la toxine botulinique pour traiter les spasmes musculaires - Google Patents

Utilisation du composant neurotoxique de la toxine botulinique pour traiter les spasmes musculaires

Info

Publication number
FR08C0034I1
FR08C0034I1 FR08C0034C FR08C0034C FR08C0034I1 FR 08C0034 I1 FR08C0034 I1 FR 08C0034I1 FR 08C0034 C FR08C0034 C FR 08C0034C FR 08C0034 C FR08C0034 C FR 08C0034C FR 08C0034 I1 FR08C0034 I1 FR 08C0034I1
Authority
FR
France
Prior art keywords
botulinum toxin
muscle spasms
neurotoxic component
treat muscle
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0034C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22634387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0034(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of FR08C0034I1 publication Critical patent/FR08C0034I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR08C0034C 1993-12-28 2008-08-27 Utilisation du composant neurotoxique de la toxine botulinique pour traiter les spasmes musculaires Active FR08C0034I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17399693A 1993-12-28 1993-12-28
EP99203920A EP1005867B2 (de) 1993-12-28 1994-12-16 Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
EP95906674A EP0737074B1 (de) 1993-12-28 1994-12-16 Botulinumtoxine zur behandlung von hyperhydrosis

Publications (1)

Publication Number Publication Date
FR08C0034I1 true FR08C0034I1 (fr) 2008-09-26

Family

ID=22634387

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0034C Active FR08C0034I1 (fr) 1993-12-28 2008-08-27 Utilisation du composant neurotoxique de la toxine botulinique pour traiter les spasmes musculaires

Country Status (9)

Country Link
EP (23) EP0737074B1 (de)
JP (33) JP3238154B2 (de)
AU (1) AU688452B2 (de)
CA (2) CA2180011C (de)
DE (23) DE69435302D1 (de)
ES (18) ES2247575T3 (de)
FR (1) FR08C0034I1 (de)
HK (6) HK1033274A1 (de)
WO (1) WO1995017904A2 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
DE69429619T2 (de) 1993-06-10 2002-09-12 Allergan, Inc. Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e
AU688452B2 (en) * 1993-12-28 1998-03-12 Allergan, Inc. Botulinum toxins for treating various disorders and associated pain
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
WO1995030431A1 (en) * 1994-05-09 1995-11-16 Binder William J Method for reduction of headache pain
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
US6780413B2 (en) 1996-09-19 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
AU2006225231B2 (en) * 1997-07-15 2006-12-07 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders
AU2008201535C1 (en) * 1997-07-15 2013-09-12 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
PT2145629E (pt) 1997-07-15 2012-04-16 Univ Colorado Regents Uso de terapia com neurotoxinas para o tratamento de perturbações urológicas e perturbações relacionadas
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
EP1053014A4 (de) 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGISCH AKTIVES HÄMAGGLUTININ VOM TYP A i(STRIDIUM BOTULINUM) UNDVERFAHREN ZU SEINER VERWENDUNG
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6649161B1 (en) * 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
AU2001276005A1 (en) * 2000-08-02 2002-02-13 Allergan Sales, Inc. Method for treating a neoplasm
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
KR20030018827A (ko) * 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
MXPA05003936A (es) * 2002-10-15 2005-06-17 Allergan Inc Terapias y procedimientos odontologicos con toxina botulinica.
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
WO2004078199A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
ES2381091T3 (es) * 2003-03-06 2012-05-23 Botulinum Toxin Research Associates, Inc. Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
FR2857595B1 (fr) * 2003-07-18 2005-10-07 Sod Conseils Rech Applic Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US7276244B2 (en) 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
EP1715888B1 (de) * 2004-02-12 2007-08-01 Philip Radovic Behandlung von abweichungen der ersten metatarsophalangealen verbindung des fusses
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
HUE025656T2 (en) 2004-03-03 2016-04-28 Revance Therapeutics Inc Topical application of botulotoxins and transdermal delivery
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1747782A1 (de) 2005-07-19 2007-01-31 Cesare Montecucco Produkte zur topischen Anwendung enthaltend Lysophospholipide und Fettsäuren
US7910116B2 (en) 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
US8518414B2 (en) 2005-11-17 2013-08-27 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2007095486A1 (en) * 2006-02-13 2007-08-23 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
EP2134257A4 (de) 2007-03-30 2014-03-05 Anders Fagergren Quantifizierung von mechanischen und neuralen beiträgen zur spastizität
KR101722038B1 (ko) 2007-07-26 2017-04-03 레반스 테라퓨틱스, 아이엔씨. 항미생물 펩티드, 조성물, 및 이용 방법
EP2072039A1 (de) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Verwendung eines neurotoxischen Bestandteils des Clostridium-botulinum-Toxinkomplexes zur Verringerung oder Verhütung von Nebenwirkungen
US8470337B2 (en) 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
KR102005930B1 (ko) 2008-12-31 2019-07-31 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제
BRPI1015938A2 (pt) 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
RU2545453C2 (ru) * 2013-03-21 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения переломов нижней челюсти
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
KR101677710B1 (ko) * 2014-06-30 2016-11-21 (주)메디톡스 보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CN109803672A (zh) * 2016-09-13 2019-05-24 阿勒根公司 稳定的非蛋白质梭菌毒素组合物
US11191819B2 (en) * 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
RU2732204C1 (ru) * 2020-01-28 2020-09-14 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Способ лечения головных болей напряжения по Гурову-Левину
CA3194375A1 (en) * 2020-10-07 2022-04-14 Hak Kun Kim Vacuum drying method for botulinum toxin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
JP4381477B2 (ja) * 1993-01-15 2009-12-09 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド 筋膜疼痛症候群の治療方法
WO1994028923A1 (en) * 1993-06-10 1994-12-22 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
DE69429619T2 (de) * 1993-06-10 2002-09-12 Allergan, Inc. Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
AU688452B2 (en) * 1993-12-28 1998-03-12 Allergan, Inc. Botulinum toxins for treating various disorders and associated pain
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
WO1995030431A1 (en) * 1994-05-09 1995-11-16 Binder William J Method for reduction of headache pain
JP2001104991A (ja) * 1999-10-12 2001-04-17 Toyoaki Kubota 循環水の有機質除去剤

Also Published As

Publication number Publication date
EP1010431B1 (de) 2005-03-30
DE69435243D1 (de) 2009-11-19
DE69435270D1 (de) 2010-04-01
DE122009000038I1 (de) 2009-11-05
ES2207910T3 (es) 2004-06-01
JP2002104991A (ja) 2002-04-10
JP2010209105A (ja) 2010-09-24
AU688452B2 (en) 1998-03-12
EP1486214A1 (de) 2004-12-15
EP1010431A2 (de) 2000-06-21
DE69435330D1 (de) 2011-01-27
DE69434319D1 (de) 2005-05-04
ES2332905T3 (es) 2010-02-15
HK1106700A1 (en) 2008-03-20
JP2012197287A (ja) 2012-10-18
DE69435276D1 (de) 2010-04-08
DE69434535D1 (de) 2005-12-08
EP1591129A3 (de) 2005-11-16
DE69434535T2 (de) 2006-07-20
DE69435194D1 (de) 2009-04-16
ES2340172T3 (es) 2010-05-31
DE69427869T2 (de) 2002-04-11
EP0770395B1 (de) 2001-10-24
JP2008056683A (ja) 2008-03-13
ES2237033T5 (es) 2010-10-29
DE69433394T2 (de) 2004-10-14
ES2247575T3 (es) 2006-03-01
ES2163090T3 (es) 2002-01-16
JP2002114706A (ja) 2002-04-16
ES2355491T3 (es) 2011-03-28
EP1005867B2 (de) 2010-02-17
EP1366771A3 (de) 2003-12-10
JP2002104990A (ja) 2002-04-10
ES2237033T3 (es) 2005-07-16
JP2012188433A (ja) 2012-10-04
DE69434319T2 (de) 2006-03-09
HK1070831A1 (en) 2005-06-30
DE69434319T3 (de) 2011-02-17
EP1598077B1 (de) 2009-11-04
JP2010202660A (ja) 2010-09-16
WO1995017904A2 (en) 1995-07-06
EP1005867A2 (de) 2000-06-07
ES2319860T3 (es) 2009-05-14
EP1502600A1 (de) 2005-02-02
EP1591129A2 (de) 2005-11-02
DE69435321D1 (de) 2010-12-16
JP2010202659A (ja) 2010-09-16
EP2027872B1 (de) 2010-07-14
ES2223393T3 (es) 2005-03-01
EP1421948A3 (de) 2004-06-16
JP2006160755A (ja) 2006-06-22
DE69434610D1 (de) 2008-08-21
EP1757325B1 (de) 2010-11-03
EP1147775B1 (de) 2009-03-04
DE69427869D1 (de) 2001-09-06
EP1147775A2 (de) 2001-10-24
DE122008000042I1 (de) 2009-01-02
EP1600163A1 (de) 2005-11-30
EP1591129B1 (de) 2010-02-24
ES2334357T3 (es) 2010-03-09
EP1563843B1 (de) 2013-08-07
JP2002087987A (ja) 2002-03-27
CA2180011C (en) 2001-05-15
EP1072270B1 (de) 2005-10-19
DE69428813T2 (de) 2002-04-04
EP1005867A3 (de) 2001-06-13
DE69435302D1 (de) 2010-08-26
EP1010431A3 (de) 2001-05-16
DE69434008T2 (de) 2005-09-22
DE69434511D1 (de) 2006-03-02
DE69434443T2 (de) 2006-05-24
EP1366771A2 (de) 2003-12-03
JP2012167116A (ja) 2012-09-06
JP2012167117A (ja) 2012-09-06
DE69434610T2 (de) 2008-11-27
EP1366770B1 (de) 2005-07-27
ES2159624T3 (es) 2001-10-16
EP1790352B1 (de) 2008-07-09
EP1103267B1 (de) 2004-09-15
EP1366770A3 (de) 2004-03-17
ES2242126T3 (es) 2005-11-01
EP1147776B1 (de) 2010-12-15
AU1516295A (en) 1995-07-17
EP1477183A1 (de) 2004-11-17
CA2682117A1 (en) 1995-07-06
DE69434540D1 (de) 2009-03-26
ES2248780T3 (es) 2008-06-16
EP1005867B1 (de) 2003-12-03
EP1366771B1 (de) 2008-03-26
JP2008037877A (ja) 2008-02-21
DE69435249D1 (de) 2009-12-17
EP1421948A2 (de) 2004-05-26
EP1790352A1 (de) 2007-05-30
JP2002087988A (ja) 2002-03-27
ES2339865T3 (es) 2010-05-26
EP1602379A1 (de) 2005-12-07
JP2002097145A (ja) 2002-04-02
JP2006160756A (ja) 2006-06-22
EP1477183B1 (de) 2005-11-02
DE69435116D1 (de) 2008-08-21
ES2251651T3 (es) 2008-07-16
ES2246800T3 (es) 2006-03-01
EP1600163B1 (de) 2010-02-17
DE69435149D1 (de) 2008-11-20
EP1103267A1 (de) 2001-05-30
DE122008000043I1 (de) 2008-11-20
JP2008056682A (ja) 2008-03-13
JP2010202661A (ja) 2010-09-16
JP2012167114A (ja) 2012-09-06
JP2002097156A (ja) 2002-04-02
JP2012167115A (ja) 2012-09-06
EP1366770A2 (de) 2003-12-03
JP2006160754A (ja) 2006-06-22
DE69433394D1 (de) 2004-01-15
EP1563843A1 (de) 2005-08-17
DE69428813D1 (de) 2001-11-29
ES2309973T3 (es) 2008-12-16
JP2008063339A (ja) 2008-03-21
WO1995017904A3 (en) 1995-10-19
EP1010431B2 (de) 2010-07-14
JP2002068989A (ja) 2002-03-08
EP1757325A1 (de) 2007-02-28
EP0770395A1 (de) 1997-05-02
JP2006160753A (ja) 2006-06-22
JPH09507234A (ja) 1997-07-22
JP2013006865A (ja) 2013-01-10
EP1072270A2 (de) 2001-01-31
EP0737074A1 (de) 1996-10-16
EP1488803B1 (de) 2008-03-26
EP1598077A1 (de) 2005-11-23
EP1147776A2 (de) 2001-10-24
HK1033274A1 (en) 2001-08-24
EP1072270A3 (de) 2002-08-07
ES2207910T5 (es) 2010-05-21
JP2007262086A (ja) 2007-10-11
DE69434443D1 (de) 2005-09-01
HK1071071A1 (en) 2005-07-08
EP2027872A1 (de) 2009-02-25
JP2008031176A (ja) 2008-02-14
JP2002087984A (ja) 2002-03-27
EP1488803A1 (de) 2004-12-22
ES2347384T3 (es) 2010-10-28
EP1147775A3 (de) 2003-01-15
JP2002087985A (ja) 2002-03-27
HK1072375A1 (en) 2005-08-26
HK1064599A1 (en) 2005-02-04
EP1502600B1 (de) 2009-10-07
DE69434511T2 (de) 2006-07-13
EP0737074B1 (de) 2001-08-01
JP2002087986A (ja) 2002-03-27
JP3238154B2 (ja) 2001-12-10
DE69434008D1 (de) 2004-10-21
CA2180011A1 (en) 1995-07-06
DE69433394T3 (de) 2010-08-12
EP1421948B1 (de) 2008-10-08
DE69434540T2 (de) 2009-06-18
EP1147776A3 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
FR08C0034I1 (fr) Utilisation du composant neurotoxique de la toxine botulinique pour traiter les spasmes musculaires
PT936908E (pt) Derivados anticonvulsivos uteis no tratamento de esclerose lateral amiotrofica (ela)
DE69631901D1 (de) Verfahren zur verminderung der korrosivität und acidität von rohöl
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
FR2533058B1 (fr) Composant de construction a isolation phonique et son utilisation pour la construction de superstructures, d'infrastructures, de tunnels et de vehicules
DE69429968D1 (de) Kolonne und Kolonnenvorrichtung für Flüssigchromatographie, und Verfahren zum Gebrauch dieser Kolonnenvorrichtung
DE69634103D1 (de) Gerät zum Oberflächenbearbeiten von heissgewalzten Stahlmaterialien
EE200100511A (et) Meetod neuroloogiliste või neuropsühhiaatriliste häirete käitluseks
FI953483A (fi) Jätekaasuöljyn käsittely
DE69603891D1 (de) Reduktion von hydrolysierbare Kationen in Rohölen
FR2699959B1 (fr) Procédé de déshydratation et/ou dessalage et de fractionnement simultané d'un effluent de gisement pétrolier.
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
FR2711076B1 (fr) Dispositif étanche et déformable élastiquement pour le débatissage de la couche résiduelle.
BR9302861A (pt) Escórias sintéticas para tratamento de aços líquidos
FR2708296B1 (fr) Rail-piste pour voies de véhicules guidés.
FI924250A0 (fi) Tien, lentokentän tai vastaavan puhdistuslaitteisto
DE59401516D1 (de) Lenkeinrichtung für Gleiskettenlaufwerke
DE69433027D1 (de) Mehrzwecke funktionelle Flüssigkeit für landwirtschaftliche Maschine oder Baumaschine
KR950018294U (ko) 자동차의 스티어링 기어박스
KR970001603U (ko) 무한궤도 주행장치의 토사방지장치
DE59604915D1 (de) Entschwefelungsmittel zur koinjektions-behandlung von roheisenschmelzen
KR940019222U (ko) 자동차용 조향중간축의 체결밴드
FR2714843B1 (fr) Gant ou moufle pour la pratique du ski.
KR950001045U (ko) 차량용 물기 제거구
KR960017274U (ko) 피견인차의 조향장치